Estimating The Fair Value Of Revolution Medicines, Inc. (NASDAQ:RVMD)
21 Stocks to Play a 'Magical Moment' in Healthcare -- Barrons.com
Revolution Medicines Is Maintained at Overweight by Barclays
Barclays Maintains Revolution Medicines(RVMD.US) With Buy Rating, Raises Target Price to $60
Revolution Medicines Added to JPMorgan Focus List Due to NSCLC Asset
J.P. Morgan Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $54
J.P. Morgan analyst Eric Joseph maintains $Revolution Medicines(RVMD.US)$ with a buy rating, and maintains the target price at $54.According to TipRanks data, the analyst has a success rate of 53.9%